



A Nicholas Hall report on Global OTC Mergers & Acquisitions





A Nicholas Hall report on Global OTC Mergers & Acquisitions

In a fragmented OTC market, efficiencies of scale cannot be achieved by organic growth alone, and many players have turned to M&A for expansion.

In a record-breaking period for M&A activity in OTC (with a total deal value estimated at more than the previous 7 years combined), 2014-15 saw some landscape-altering takeovers and joint-ventures. Highlights include:

- GSK and Novartis formed a consumer healthcare j-v comprising both companies' OTC businesses in March 2015
- Bayer completed acquisitions of Merck Consumer Care from MSD and privately-held Chinese • OTC player Kunming Dihon in quick succession in late 2014
- Perrigo bought Belgium's Omega Pharma in March 2015, and subsequently picked up a handful • of OTC brands from Aspen and GSK (before itself becoming the subject of takeover interest)
- Actavis emerged triumphant in the bidding war for Allergan in early 2015 (and the combined ٠ company is taking the first steps towards being acquired by Pfizer)
- Meda purchased key Italian OTC player Rottapharm | Madaus in late 2014 •
- Prestige Brands snapped up Insight Pharmaceuticals in 2014 Ō
- Sun Pharma's acquisition of Ranbaxy (from Japan's Daiichi Sankyo) was the biggest deal • impacting India's healthcare market in 2015

Among all this top-level activity, numerous smaller deals have also helped subtly alter the OTC landscape. And there remains a wealth of opportunities yet to be exploited: companies from around the globe, spread across categories, geographies and specialisations. Canny OTC players will spot their development potential and look to invest, either in outright acquisition targets, potential j-v partners or companies with an OTC portfolio ripe for purchase. The fast-growth emerging markets of Asia and Latin America will almost certainly be a focus in future, while companies with Rx-to-OTC switch assets will command a premium.

To learn about the M&A strategies of leading players, the hottest targets for acquisition or partnership, and the key trends driving M&A in the OTC market, look no further than M&A: A Nicholas Hall report on Global OTC Mergers & Acquisitions. Who is yet to sate their appetite

Naucido Han.

NICHOLAS HALL Chairman & CEO Nicholas Hall Group of Companies

strengths & weaknesses of What are the recently-expanded companies such as Bayer, GSK, Prestige Brands

for expansion?

Chapters

Global OTC Overview

A look at the OTC market as a whole, highlighting key trends and growth factors in each region

M&A Review 2013-16

Detailed analysis of the key deals year by year on a global, regional and local level, plus a multiples table for comparing amounts paid in selected deals

Trends in M&A

Identifying trends and reviewing key lessons from past M&A

M&A at the OTC Top Table

Profiles of the world's 20 leading OTC marketers including Bayer, GSK, J&J, Pfizer and Sanofi, featuring acquisition strategies, past M&A highlights and future direction, plus year-end 2015 sales data from Nicholas Hall's DB6 Global OTC Database

Leading M&A Targets

100 acquisition / j-v targets from around the world, covering their strengths, notable assets and top markets, plus 2015 OTC sales, growth and leading brands

Eye on the OTC Horizon and Future of M&A

The outlook for the OTC industry and factors that will shape future M&A activity

Appendix: M&A Register 2005-16

Listing all the deals with an OTC impact, back to 2005, including a summary of the big OTC deals for each year

Key questions addressed in this report

How has the flurry of M&A activity changed the OTC landscape?

What will the new-found OTC synergies mean for the market?

What are the most likely targets for the next round of M&A?

Who has emerged in

the best shape?

PRIORITY ORDER FORM FOR M&A: A Nicholas Hall report on Global OTC Mergers & Acquisitions

A global licence will be required if you wish to put this report on your company's intranet. All prices are quoted in British Pound Sterling.

Please tick as appropriate. I would like to order:

Full report:	If ordered before 19th February 20% discount	If ordered before 11th March 10% discount	Orders at full rate after 11th March
Global Licence	£12,000	£13,500	£15,000
	£9,600	£10,800	£12,000

DELIVERY DETAILS

Mr/Mrs/Ms/Dr/Other	_ First Name
Last Name	
Job Title	
Company	
Address	
Country	
Tel	
Email	

PAYMENT DETAILS

Please invoice my company quoting order number /reference:

(material will be sent when full payment is received)

VAT ID Number (EU only):_____

Signed:

___ Date: DD / MM / YYYY

If you do not wish to	receive future int	formation from us, plea	se
tick as appropriate:	Mail Fax	Email	

Please fax the completed order form to +44 (0) 1702 220 241 or email to info@NicholasHall.com



Nicholas Hall Europe Limited

 35 Alexandra Street, Southend-on-Sea, Essex, SS1 1BW, UK

 T: +44 (0) 1702 220 200
 F: +44 (0) 1702 430 787

 E: info@NicholasHall.com
 W: www.NicholasHall.com



Save up to £3,000 on early orders

Published in PDF format

Quick Delivery

Versatile Format

See Nicholas Hall's full OTC reports catalogue at bit.ly/NHReports



Nicholas Hall Group of Companies offers the world's most complete OTC marketing & business solutions

Dedicated to benchmarking consumer healthcare markets and providing business solutions, we are specialists in OTC, with an international network of contacts, offering data & analysis, strategic advice and competitive intelligence on a global, regional or local basis.

Latest Nicholas Hall Reports:



Global OTC Analgesics

This report breaks down this integral category to give consumer healthcare executives detailed insight into the uncertainties that are facing brands in today's market, as well as the growth drivers and new opportunites.


Published in November 2015



Nicholas Hall's Global OTC Markets

This report looks at the 12 largest OTC markets. While these markets lead the global industry, their performances differ wildly, showing the diverse nature of the consumer healthcare industry.

Published in September 2015



Global OTC Cough, Cold & Allergy This comprehensive report offers a detailed analysis of the CCA market from both a global and country level, giving OTC marketers a detailed insight into the trends and developments that are impacting both



Nicholas Hall's OTC YearBook 2015 Nicholas Hall's best-selling unique reference book contains comprehensive market data through December 2014 drawn from our **DB6** global OTC database.

Published in April 2015



Women's Health: Obstacles & Opportunities

This report analyses the market for a range of OTC options, considering products positioned for gender-specific concerns as well as more general ailments, covering areas including weight management, feminine intimate care, and migraine.

Published in March 2015

brands and consumers.

Published in June 2015



Lifestyle OTCs

Looking at essential areas including obesity treatments and heart health, this report puts a spotlight on the impact of e-cigarettes on traditional NRTs, potential growth drivers for eye sales, and much more.

Published in December 2014



Global OTC Gastrointestinals

Discover all there is to know about GIs, from PPI switches in the US to dynamism in Latin America and dereimbursement in Europe. Available as a full publication or individual country chapters.

Published in February 2015

Get in touch!

Discover the world of OTC with the Nicholas Hall Group of Companies. Our range of services covers everything from consultancy and competitive intelligence to events and executive recruitment.

Whatever your needs are in consumer healthcare, we'd like to hear from you!

